IV N-acetylcysteine

Phase 3Small molecule

UUniversity of Cape Town

IV N-acetylcysteine is one of 30 small molecule programs targeting Drug-Induced Hepatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Drug-Induced HepatitisActive, not recruiting

HysterectomyActive, not recruiting

Drug-Induced HepatitisPhase 2/Phase 3

Active, not recruiting

HysterectomyPhase 3

Active, not recruiting

Competition

Competitive Landscape

132 competitors in Hysterectomy

#DrugCompanyPhaseTrials

Cervidil

Pfizer

Phase 3

1 2

Elavil

AstraZeneca

Phase 3

1 3

Arcoxia

Novartis

Phase 3

1 4

Tylenol

KKenvue Brands

Phase 3

4 5

Epsom Salt

FFresenius Kabi Oncology Ltd.

Phase 3

3 6

Celebrex

PPhiladelphia Eye Associates

Phase 3

2 7

Dilaudid

RRhodes Pharmaceuticals, L.P.

Phase 3

1 8

Ketalar

AAultman Health Foundation

Phase 3

1 9

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

2 10

Spravato

WWim Janssens

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Hysterectomy

NCT06039566

Clinical

Trials by Indication[1]

Hysterectomy1 trial

NAC vs Placebo on Opioid Use for Hysterectomy

Recruiting·MMedical University of South Carolina·Phase 3·NCT06039566·240 enrolled

Drug-Induced Hepatitis1 trial

A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis

Completed·UUniversity of Cape Town·Phase 2/3·NCT02182167·102 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for IV N-acetylcysteine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IV N-acetylcysteine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IV N-acetylcysteine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Cape Town company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Cape Town

IV N-acetylcysteine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Hysterectomy1 trial

Drug-Induced Hepatitis1 trial

References

Drug Info

Quick Facts

Related News